πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,196 results for β€œGE” Clear

  1. The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

    Century Therapeutics

    systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]

    phase 1 other active

    1 trial

  2. The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)

    Sinobioway Cell Therapy Co.,

    Lymphoma

    phase 1 mab active

    1 trial

  3. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI β‰₯ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) β‰₯16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-MΓΌllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  4. The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatment of type 2 diabetes mellitus in adults and children aged 10 years and above, and heart failure and chronic kidney disease in adults patiens.

    Lacuna Pharma Pty Ltd

    Not applicable (submitted trial is a BE study in healthy subjects.

    phase 1 other active

    1 trial

  5. This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adult participants with Chronic Inducible Urticaria (CIndU) to assess if it is safe and improves reactions to known CIndU triggers.

    Lacuna Pharma Pty Ltd

    Chronic Inducible Urticaria

    phase 1 other active

    1 trial

  6. This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body and if it can control the disease of people diagnosed with advanced cancer that has not responded to treatment, has returned after it has been treated, or cannot be treated by surgery, drugs, or any other known treatments.

    Celgene Europe Limited

    Part C: advanced or unresectable STs (Spain only), Part B : r/r diffuse large B cell lymphoma (DLBCL) (Cohort 1), advanced basal cell carcinoma (BCC) (Cohort 2), r/r DLBCL under an alternative dosing regimen (Cohort 3), Part A: advanced or unresectable solid tumors (STs) and relapsed and/or refractory (r/r) advanced non-Hodgkin's lymphomas (NHLs)

    phase 1 other active

    1 trial

  7. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  8. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Hoffmann-La Roche

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  9. Tissue Plasminogen Activator (tPA)

    Hospital Authority, Hong Kong

    Peritoneal Dialysis

    phase 1 small molecule terminated

    1 trial

  10. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  11. Tranexamic AcidοΌ›

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Iatrogenic Endobronchial Bleeding

    phase 1 small molecule active

    1 trial

  12. Treatment of advanced or metastatic triple negative breast cancer with tumor infiltrating lymphocytes (TILs).

    The George Institute

    advanced or metastasic triple-negative breast cancer

    phase 1 other active

    1 trial

  13. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

    Genmab A/S

    Advanced Malignant Solid Tumors

    phase 1 other active

    1 trial

  14. Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors

    Genmab A/S

    Metastatic or advanced malignant solid tumors

    phase 1 other active

    1 trial

  15. Triheptanoin

    Ultragenyx UK Limited

    Pyruvate Dehydrogenase Complex Deficiency

    phase 1 small molecule active

    1 trial

  16. Triheptanoin

    Ultragenyx UK Limited

    Glycogen Storage Disease Type I

    phase 1 small molecule completed

    1 trial

  17. UI059

    United Therapeutics Europe Ltd

    GERD

    phase 1 small molecule completed

    1 trial

  18. VEGF Trap

    Regeneron UK Limited

    Neovascular Age Related Macular Degeneration

    phase 1 small molecule completed

    1 trial

  19. VEGF Trap

    Regeneron UK Limited

    Macular Degeneration

    phase 1 small molecule completed

    1 trial

  20. VEGF Trap-Eye

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 1 small molecule completed

    1 trial

  21. Valemetostat Tosylate, DS-8201a, Datopotamab deruxtecan, Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  22. Vancomycin Pre-Treatment

    Seres Therapeutics

    Allogeneic Hematopoietic Stem Cell Transplantation

    phase 1 small molecule completed

    1 trial

  23. Vaporized Marijuana

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Usage

    phase 1 small molecule completed

    1 trial

  24. Venetoclax

    Karyopharm Therapeutics Inc

    Diffuse Large B-cell Lymphoma

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources